A new drug has shown so much promise for reducing heart attacks and stroked induced by bad cholesterol in half. There is now a 50% reduction in the risks of death or hospitalization faced by strokes and heart attack patients due to the ability of this new cholesterol-reducing drug. This new drug is still largely experimental, but it is manufactured by Sanofi and Regeneron Pharmaceuticals, two reputable pharmaceuticals in heart drugs manufacturing.
Alirocumab, as the new cholesterol-reducing drug is called, has showed so much effectiveness and promise in clinical trials involving 2,341 patients, but medical authorities are still calling for caution in its administration and calls for more tests to be done before it is approved for use. Medical authorities request that more tests be done on a larger number of people across board to certify its effectiveness for cutting in half the need for hospitalization for heart and stroke patients.
Alirocumab was found effective in targeting the PCSK9 protein, which has been fingered in cardiovascular risks. It has also been proved effective in lowering LDT, a bad cholesterol that contributes to strokes and heart related diseases. Amgen and Pfizer have undertaken the development and production of this drug, and it is anticipated to greatly bring hopes to millions of patients suffering from cardiovascular diseases. Alirocumab is injectable, and successes with clinical trials have been reported at the European Society of Cardiology meeting that held in Barcelona.
Dr. Jennifer Robinson, a cardiologist from the University of Iowa that led the study showed excitements with Alirocumab, and stated that “to have this result emerge so quickly in this study is very encouraging.” But Dr. Patrick O’Gara from the Brigham and Women’s Hospital in Boston expressed caution by saying that “it’s so much wished-for that we must be careful,” and here he was advocating for more tests.